The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [41] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Asahina, Hajime
    Tamura, Yosuke
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Seki, Yoshitaka
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Yamada, Yasuhide
    Coates, Andrew
    Chiu, Yi-Lin
    Li, Xiaohui
    Pradhan, Rajendra
    Ansell, Peter J.
    McKeegan, Evelyn M.
    McKee, Mark D.
    Carlson, Dawn M.
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1477 - 1486
  • [42] Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
    Zimmer, Lisa
    Livingstone, Elisabeth
    Krackhardt, Angela
    Schultz, Erwin S.
    Goppner, Daniela
    Assaf, Chalid
    Trebing, Dietrich
    Stelter, Kai
    Windemuth-Kieselbach, Christine
    Ugurel, Selma
    Schadendorf, Dirk
    EUROPEAN JOURNAL OF CANCER, 2021, 158 : 72 - 84
  • [43] Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
    Doi, Toshihiko
    Yoshino, Takayuki
    Shitara, Kohei
    Matsubara, Nobuaki
    Fuse, Nozomu
    Naito, Yoichi
    Uenaka, Kazunori
    Nakamura, Takashi
    Hynes, Scott M.
    Lin, Aimee Bence
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1043 - 1053
  • [44] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Doi, Toshihiko
    Fuse, Nozomu
    Yoshino, Takayuki
    Kojima, Takashi
    Bando, Hideaki
    Miyamoto, Hideaki
    Kaneko, Masato
    Osada, Motonobu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 89 - 98
  • [45] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Toshihiko Doi
    Nozomu Fuse
    Takayuki Yoshino
    Takashi Kojima
    Hideaki Bando
    Hideaki Miyamoto
    Masato Kaneko
    Motonobu Osada
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 89 - 98
  • [46] Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
    Saif, Muhammad Wasif
    Sarantopoulos, John
    Patnaik, Amita
    Tolcher, Anthony W.
    Takimoto, Chris
    Beeram, Murali
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1565 - 1573
  • [47] Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
    Muhammad Wasif Saif
    John Sarantopoulos
    Amita Patnaik
    Anthony W. Tolcher
    Chris Takimoto
    Murali Beeram
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1565 - 1573
  • [48] Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
    Kawazoe, Akihito
    Yamaguchi, Kensei
    Yasui, Hisateru
    Negoro, Yuji
    Azuma, Mizutomo
    Amagai, Kenji
    Hara, Hiroki
    Baba, Hideo
    Tsuda, Masahiro
    Hosaka, Hisashi
    Kawakami, Hisato
    Oshima, Takashi
    Omuro, Yasushi
    Machida, Nozomu
    Esaki, Taito
    Yoshida, Kazuhiro
    Nishina, Tomohiro
    Komatsu, Yoshito
    Han, Shi R.
    Shiratori, Shinichi
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 97 - 106
  • [49] Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study
    Fujiwara, Yutaka
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Yoshikawa, Shusuke
    Yamamoto, Noboru
    Tsutsumida, Arata
    Nokihara, Hiroshi
    Namikawa, Kenjiro
    Mukaiyama, Akihira
    Zhang, Fanghong
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 259 - 268
  • [50] The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors
    Daga, Haruko
    Hida, Toyoaki
    Ishikawa, Shizu
    Shimizu, Junichi
    Tokunaga, Shinya
    Horio, Yoshitsugu
    Kobayashi, Ken
    Takeda, Koji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (09) : 1067 - 1073
12345